Mohan R, Liu AY, Brown PD, Mahajan A, Dinh J, Chung C, McAvoy S, McAleer MF, Lin SH, Li J, Ghia AJ, Zhu C, Sulman EP, de Groot JF, Heimberger AB, McGovern SL, Grassberger C, Shih H, Ellsworth S, Grosshans DR (2021) Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons. Neuro Oncol 23(2):284–294. https://doi.org/10.1093/neuonc/noaa182

Article  CAS  PubMed  Google Scholar 

Guclu E, Ayan IC (2023) Investigation of the Anticancer activity of DCZ0415, a small molecular inhibitor of TRIP13, in U87 Human Glioblastoma Multiforme Cells. Selcuk Med J 39(1):12–18. https://doi.org/10.30733/std.2023.01587

Article  Google Scholar 

Balana C, Vaz MA, Manuel Sepúlveda J, Mesia C, Del Barco S, Pineda E, Muñoz-Langa J, Estival A, de Las Peñas R, Fuster J, Gironés R, Navarro LM, Gil-Gil M, Alonso M, Herrero A, Peralta S, Olier C, Perez-Segura P, Covela M, Martinez-García M, Berrocal A, Gallego O, Luque R, Perez-Martín FJ, Esteve A, Munne N, Domenech M, Villa S, Sanz C, Carrato C (2020) A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14 – 01). Neuro Oncol 22(12):1851–1861. https://doi.org/10.1093/neuonc/noaa107

Article  PubMed  PubMed Central  Google Scholar 

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466. https://doi.org/10.1016/S1470-2045(09)70025-7

Article  CAS  PubMed  Google Scholar 

Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS et al (2018) First results on survival from a large phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med 16(1):142. https://doi.org/10.1186/s12967-018-1507-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee HJ, Han HJ, Lee JY, Son WC (2020) PKM2 in Canine Mammary tumors: parallels to human Breast Cancer. Comp Med 70(4):349–354. https://doi.org/10.30802/AALAS-CM-20-000013

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yin C, Lu W, Ma M, Yang Q, He W, Hu Y, Xia L (2020) Efficacy and mechanism of combination of oxaliplatin with PKM2 knockdown in Colorectal cancer. Oncol Lett 20(6):312.

Article  PubMed  PubMed Central  Google Scholar 

Verma H, Cholia RP, Kaur S, Dhiman M, Mantha AK (2021) A short review on cross-link between pyruvate kinase (PKM2) and Glioblastoma Multiforme. Metab Brain Dis 36(5):751–765. https://doi.org/10.1007/s11011-021-00690-y

Article  CAS  PubMed  Google Scholar 

Cui R, Shi XY (2015) Expression of pyruvate kinase M2 in human Colorectal cancer and its prognostic value. Int J Clin Exp Pathol 8(9):11393–11399

PubMed  PubMed Central  Google Scholar 

Dayton TL, Jacks T, Vander Heiden MG (2016) PKM2, cancer metabolism, and the road ahead. EMBO Rep 17(12):1721–1730. https://doi.org/10.15252/embr.201643300

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang C, Huang Z, Bai P, Luo G, Zhao X, Wang X (2018) Expression of pyruvate kinase M2 in human Bladder cancer and its correlation with clinical parameters and prognosis. Onco Targets Ther 11:2075–2082. https://doi.org/10.2147/OTT.S152999

Article  PubMed  PubMed Central  Google Scholar 

Zhang Z, Deng X, Liu Y, Liu Y, Sun L, Chen F (2019) PKM2, function and expression and regulation. Cell Biosci 9:52. https://doi.org/10.1186/s13578-019-0317-8

Article  PubMed  PubMed Central  Google Scholar 

Li H, Yan M, Wu X, Wang Y, Huang L (2021) Expression and clinical significance of pyruvate kinase M2 in Breast cancer: a protocol for meta-analysis and bioinformatics validation analysis. Med (Baltim) 100(18):e25545. https://doi.org/10.1097/MD.0000000000025545

Article  CAS  Google Scholar 

Yu G, Yu W, Jin G, Xu D, Chen Y, Xia T, Yu A, Fang W, Zhang X, Li Z, Xie K (2015) PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma. Mol Cancer 14:193. https://doi.org/10.1186/s12943-015-0462-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin Y, Zhai H, Ouyang Y, Lu Z, Chu C, He Q, Cao X (2019) Knockdown of PKM2 enhances radiosensitivity of Cervical cancer cells. Cancer Cell Int 19:129. https://doi.org/10.1186/s12935-019-0845-7

Article  PubMed  PubMed Central  Google Scholar 

Zhu H, Luo H, Zhu X, Hu X, Zheng L, Zhu X (2017) Pyruvate kinase M2 (PKM2) expression correlates with prognosis in solid cancers: a meta-analysis. Oncotarget 8(1):1628–1640. https://doi.org/10.18632/oncotarget.13703

Article  PubMed  Google Scholar 

Long L, Chen M, Yuan Y, Ming AL, Guo W, Wu K, Chen H (2020) High expression of PKM2 synergizes with PD-L1 in Tumor cells and immune cells to predict worse survival in human lung adenocarcinoma. J Cancer 11(15):4442–4452. https://doi.org/10.7150/jca.42610

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lockney NA, Zhang M, Lu Y, Sopha SC, Washington MK, Merchant N, Zhao Z, Shyr Y, Chakravarthy AB, Xia F (2015) Pyruvate Kinase Muscle Isoenzyme 2 (PKM2) expression is Associated with overall survival in pancreatic ductal adenocarcinoma. J Gastrointest Cancer 46(4):390–398. https://doi.org/10.1007/s12029-015-9764-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109. https://doi.org/10.1007/s00401-007-0243-4

Article  PubMed  PubMed Central  Google Scholar 

Leao DJ, Craig PG, Godoy LF, Leite CC, Policeni B (2020) Response Assessment in Neuro-Oncology Criteria for Gliomas: practical Approach using Conventional and Advanced techniques. AJNR Am J Neuroradiol 41(1):10–20. https://doi.org/10.3174/ajnr.A6358

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mukherjee J, Phillips JJ, Zheng S, Wiencke J, Ronen SM, Pieper RO (2013) Pyruvate kinase M2 expression, but not pyruvate kinase activity, is up-regulated in a grade-specific manner in human glioma. PLoS ONE 8(2):e57610. https://doi.org/10.1371/journal.pone.0057610

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun H, Zhu A, Zhang L, Zhang J, Zhong Z, Wang F (2015) Knockdown of PKM2 suppresses Tumor Growth and Invasion in Lung Adenocarcinoma. Int J Mol Sci 16(10):24574–24587. https://doi.org/10.3390/ijms161024574

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu W, Cao Y, Zhang Y, Li S, Gao J, Wang XA, Mu J, Hu YP, Jiang L, Dong P, Gong W, Liu Y (2016) Up-regulation of PKM2 promote malignancy and related to adverse prognostic risk factor in human gallbladder cancer. Sci Rep 6:26351. https://doi.org/10.1038/srep26351

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao X, Wang H, Yang JJ, Chen J, Jie J, Li L, Zhang Y, Liu ZR (2013) Reciprocal regulation of protein kinase and pyruvate kinase activities of pyruvate kinase M2 by growth signals. J Biol Chem 288(22):15971–15979. https://doi.org/10.1074/jbc.M112.448753

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cholia RP, Dhiman M, Kumar R, Mantha AK (2018) Oxidative stress stimulates invasive potential in rat C6 and human U-87 MG glioblastoma cells via activation and cross-talk between PKM2, ENPP2 and APE1 enzymes. Metab Brain Dis 33(4):1307–1326. https://doi.org/10.1007/s11011-018-0233-3

Article  CAS  PubMed  Google Scholar 

Burgenske DM, Yang J, Decker PA, Kollmeyer TM, Kosel ML, Mladek AC, Caron AA, Vaubel RA, Gupta SK, Kitange GJ, Sicotte H, Youland RS, Remonde D, Voss JS, Fritcher EGB, Kolsky KL, Ida CM, Meyer FB, Lachance DH, Parney IJ, Kipp BR, Giannini C, Sulman EP, Jenkins RB, Eckel-Passow JE, Sarkaria JN (2019) Molecular profiling of long-term IDH-wildtype glioblastoma survivors. Neuro Oncol 21(11):1458–1469. https://doi.org/10.1093/neuonc/noz129

Article  CAS  PubMed  PubMed Central  Google Scholar 

Han S, Liu Y, Cai SJ, Qian M, Ding J, Larion M, Gilbert MR, Yang C (2020) IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Br J Cancer 122(11):1580–1589. https://doi.org/10.1038/s41416-020-0814-x

Article  PubMed  PubMed Central  Google Scholar